OTCMKTS:WINTWindtree Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Windtree Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.90 +1.53 (+18.28 %) (As of 08/4/2020 09:30 AM ET) Add Compare Share Today's Range$8.43Now: $9.90▼$10.0250-Day Range$6.25MA: $7.04▼$8.3752-Week Range$4.00Now: $9.90▼$14.97Volume293,278 shsAverage Volume22,094 shsMarket Capitalization$135.60 millionP/E RatioN/ADividend YieldN/ABeta0.32 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingWindtree Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.25, Windtree Therapeutics has a potential upside of 23.7% from its current price of $9.90.Amount of Analyst CoverageWindtree Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesWindtree Therapeutics has received 147 “outperform” votes. (Add your “outperform” vote.)Underperform VotesWindtree Therapeutics has received 136 “underperform” votes. (Add your “underperform” vote.)Community SentimentWindtree Therapeutics has received 51.94% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote “Outperform” if you believe WINT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldWindtree Therapeutics does not currently pay a dividend.Dividend GrowthWindtree Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Windtree Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,484.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 14.91% of the stock of Windtree Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Windtree Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Windtree Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWindtree Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.62 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolOTCMKTS:WINT Previous SymbolNASDAQ:WINT CUSIP25466840 CIK946486 Webwww.windtreetx.com Phone215-488-9300Debt Debt-to-Equity Ratio0.29 Current Ratio2.61 Quick Ratio2.61Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$200,000.00 Price / Sales678.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.12 per share Price / Book1.93Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-27,480,000.00 Net MarginsN/A Return on Equity-42.86% Return on Assets-25.10%Miscellaneous Employees27 Outstanding Shares13,697,000Market Cap$135.60 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $9.90 +1.53 (+18.28 %) (As of 08/4/2020 09:30 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive WINT News and Ratings via Email Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions How has Windtree Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Windtree Therapeutics' stock was trading at $3.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, WINT stock has increased by 167.6% and is now trading at $9.90. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Windtree Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Windtree Therapeutics. When is Windtree Therapeutics' next earnings date? Windtree Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Windtree Therapeutics. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics Inc (OTCMKTS:WINT) posted its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.48) earnings per share for the quarter. View Windtree Therapeutics' earnings history. When did Windtree Therapeutics' stock split? How did Windtree Therapeutics' stock split work? Windtree Therapeutics shares reverse split on Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 28th 2020. An investor that had 100 shares of Windtree Therapeutics stock prior to the reverse split would have 33 shares after the split. What price target have analysts set for WINT? 1 brokerages have issued 12-month target prices for Windtree Therapeutics' stock. Their forecasts range from $12.25 to $12.25. On average, they anticipate Windtree Therapeutics' share price to reach $12.25 in the next twelve months. This suggests a possible upside of 23.7% from the stock's current price. View analysts' price targets for Windtree Therapeutics. Has Windtree Therapeutics been receiving favorable news coverage? Media stories about WINT stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Windtree Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news about Windtree Therapeutics. Who are some of Windtree Therapeutics' key competitors? Some companies that are related to Windtree Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Windtree Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Windtree Therapeutics investors own include La Jolla Pharmaceutical (LJPC), Trevena (TRVN), NovaBay Pharmaceuticals (NBY), XOMA (XOMA), CTI BioPharma (CTIC), Reshape Lifesciences (RSLS), CorMedix (CRMD), Microbot Medical (MBOT), Novavax (NVAX) and SLS International (SLS). Who are Windtree Therapeutics' key executives? Windtree Therapeutics' management team includes the following people: Mr. Craig E. Fraser, Pres, CEO & Director (Age 54)Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 53)Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 60)Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 67)Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 72) What is Windtree Therapeutics' stock symbol? Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT." Who are Windtree Therapeutics' major shareholders? Windtree Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (0.03%). Company insiders that own Windtree Therapeutics stock include James Huang and Lph Ii Investments Ltd. View institutional ownership trends for Windtree Therapeutics. Which institutional investors are buying Windtree Therapeutics stock? WINT stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Windtree Therapeutics stock in the last two years include James Huang, and Lph Ii Investments Ltd. View insider buying and selling activity for Windtree Therapeutics. How do I buy shares of Windtree Therapeutics? Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Windtree Therapeutics' stock price today? One share of WINT stock can currently be purchased for approximately $9.90. How big of a company is Windtree Therapeutics? Windtree Therapeutics has a market capitalization of $135.60 million and generates $200,000.00 in revenue each year. Windtree Therapeutics employs 27 workers across the globe. What is Windtree Therapeutics' official website? The official website for Windtree Therapeutics is www.windtreetx.com. How can I contact Windtree Therapeutics? Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
